Soufflé Therapeutics, an RNA therapeutics company co‑founded by Moderna co‑founder Bob Langer, launched with a $200 million Series A and strategic partnerships with Big Pharma to develop targeted siRNA medicines. The company intends to engineer cell‑specific siRNA delivery and precision targeting to expand RNA modalities beyond current clinical leads. Soufflé’s financing and team signal investor conviction in RNA technologies that go beyond mRNA vaccines and into targeted, durable modalities. The round underscores continued capital flow into RNA innovation and the industry’s appetite for platform plays that combine advanced delivery and target selection. Soufflé’s emergence adds to a crowded but fast‑moving RNA ecosystem where differentiation will hinge on delivery, specificity and safety in clinical settings.